Prime Minister Opens e-Therapeutics' Drug Discovery Centre near Oxford

27 Feb 2012 07:00

Prime Minister Opens e-Therapeutics' Drug Discovery Centre near Oxford

Oxford and Newcastle, UK, 26 February 2012 - e-Therapeutics announces that the UK's Prime Minister, the Right Honourable David Cameron, MP, has opened the Company's new drug discovery centre at Long Hanborough near Oxford.

The centre, which is located in the Prime Minister's parliamentary constituency, will spearhead e-Therapeutics' pioneering work in network pharmacology, a distinctive approach to the discovery of medicines with potential to produce new and improved treatments for complex diseases such as cancer.

The Prime Minister said: "e-Therapeutics is a fascinating and innovative business in my constituency. Their use of pioneering science has the potential to deliver great results and I very much hope that their treatments are successful."

Professor Malcolm Young, founder and CEO of e-Therapeutics, said: "We are delighted to have the Prime Minister open our new drug discovery centre near Oxford, which is a world centre of excellence in the science that underpins our business."

About e-Therapeutics

e-Therapeutics is pioneering the new science of network pharmacology in drug discovery. Scientists at the Company's Network Pharmacology Centre near Oxford are seeking novel treatments for cancer and degenerative diseases of the nervous system. During 2012, e-Therapeutics plans to advance four drugs derived from network pharmacology research into clinical trials. These include potential treatments for cancer, major depressive disorder and resistant bacterial infections.e-Therapeutics has a site in Newcastle-upon-Tyne in addition to its new centre near Oxford. The Company is listed on the AIM market of the London Stock Exchange (ticker ETX). For more information please visit www.etherapeutics.co.uk.

About network pharmacology

Based on advances in chemical biology and network science, network pharmacology is a distinctive new approach to drug discovery. It involves application of network analysis to determine the set of proteins most critical in any disease, and then chemical biology to identify molecules capable of targeting that set of proteins. By addressing the true complexity of disease and by seeking to harness the ability of drugs to influence many different proteins, network pharmacology differs from conventional drug discovery approaches, which have generally been based on highly specific targeting of a single protein. Network pharmacology has the potential to provide new treatments for complex diseases where conventional approaches have failed to deliver satisfactory therapies. More information is available at www.etherapeutics.co.uk

Copyright Business Wire 2012